Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
Article content
$124.2 million in cash and cash equivalents and marketable securities provides runway as of March 31, 2025
Article content
CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025.
Article content
'During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline programs,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'We announced a strategic partnership with DCx Biotherapeutics to out-license our discovery platforms, and we are exploring a full range of strategic alternatives and partnerships across our portfolio. We are well-positioned from an operational and financial standpoint to drive our clinical pipeline to key inflection points and remain on track to report initial data for both the LIONS and POLAR trials in the second half of this year.'
Article content
First Quarter 2025 and Recent Portfolio Highlights:
Article content
Announced out-licensing of its discovery platforms to DCx Biotherapeutics
Repare announced it out-licensed its early-stage discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ('DCx'). In connection with this agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% equity position in DCx, including certain dilution protection rights, and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low single-digit sales royalties for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare's preclinical research employees.
Article content
RP-3467: Potential best-in-class, oral Polθ ATPase/helicase inhibitor
Repare is conducting a Phase 1 clinical trial of RP-3467 (POLAR), dosing patients alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. POLAR is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3647 alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma.
Upcoming expected milestone:
Q3 2025: Topline safety, tolerability and early efficacy data from the POLAR trial in monotherapy and in combination with olaparib.
Article content
RP-1664: First-in-class, oral selective PLK4 Inhibitor
Repare completed enrolment of 29 patients in its Phase 1 LIONS clinical trial, evaluating RP-1664 as a monotherapy in adult and adolescent patients with TRIM37-high solid tumors. LIONS is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664.
Upcoming expected milestone:
Article content
Lunresertib (RP-6306)
Repare is currently evaluating lunresertib in combination with Debio 0123, a highly selective, brain-penetrant, clinical WEE1 inhibitor, in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations as part of an ongoing 50/50 cost sharing collaboration with Debiopharm. Repare does not intend to continue to develop lunresertib in any other trials, absent securing a partnership with a development partner.
Article content
Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of March 31, 2025 were $124.2 million, as compared to $152.8 million as of December 31, 2024. The Company believes that its cash, cash equivalents, and marketable securities are sufficient to fund its current operational plans through 2027.
Revenue from collaboration agreements: Revenue from collaboration agreements was nil and $52.4 million for the three months ended March 31, 2025 and 2024, respectively.
Research and development expense, net of tax credits (Net R&D): Net R&D expenses were $20.3 million and $33.0 million for the three months ended March 31, 2025 and 2024, respectively.
General and administrative (G&D) expenses: G&A expenses were $7.7 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively.
Net income (loss): Net loss was $30.1 million, or $0.71 per diluted share, and $13.2 million, or $0.30 per diluted share, for the three months ended March 31, 2025 and 2024, respectively.
Article content
About Repare Therapeutics Inc.
Article content
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
Article content
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of its discovery platforms to DCx, including the potential benefits of the transaction and the receipt of out-licensing, clinical and commercial milestone payments and royalties under the out-license agreement; the Company's plans for exploring strategic alternatives and partnerships across the clinical portfolio, including the Company's plans to seek a partner to fund further clinical development of lunresertib and other assets; the Company's anticipated cash runway; the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company's product candidates including the advancement of its three ongoing clinical trials. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's ability to successfully pursue a strategic transaction on attractive terms, or at all; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025., and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
4 hours ago
- CBC
'Lots of turbulence': Air Canada flyers describe cancellation, rebooking chaos amid strike
Social Sharing Travellers in Canada and abroad scrambled to secure flights on Sunday after striking Air Canada flight attendants defied a federal back-to-work order, abruptly halting the airline's plans to resume operations. Lila Rousseaux, who was scheduled to fly home with her family from Zurich to Toronto on Sunday, told CBC News she spent all of Saturday glued to her phone for news about whether her flight would be cancelled. At 12:30 a.m. on Sunday, she was informed it was. "I spent one and a half hours on the phone with the agent ... lots of turbulence," Rousseaux said. "There was a lot of inflexibility in terms of what can be done," she said, adding that her suggestions to take a train to Amsterdam to catch a plane or fly directly to the U.S. before driving across the border were rebuffed by the agent. WATCH | Lila Rousseaux describes 'turbulence' of rebooking flight: Want Air Canada to reroute your flight? Prepare for 'turbulence,' says this passenger 3 hours ago Air Canada says it plans to restart flights Monday evening after striking flight attendants defied the federal government's back-to-work order Sunday morning. For Lila Rousseaux, a longtime Air Canada customer, the weekend work stoppage has resulted in inflexibility from the airline as she and her family try to reroute their way home. Rousseaux said she finally booked an "awful" overnight flight to Atlanta, lamenting that she is no longer being seated with children. "The distress in my family is very acute," she said. Ottawa moved to intervene in the labour dispute on Saturday, less than 12 hours after the strike and lockout took effect, with federal Jobs Minister Patty Hajdu saying she was invoking Section 107 of the Canada Labour Code to ask the Canada Industrial Relations Board (CIRB) to send the two sides to binding arbitration and to order the airline and its flight attendants back to work in the meantime. The Montreal-based airline subsequently announced early Sunday that it planned to resume flights in the evening, but just hours later, the union representing more than 10,000 flight attendants said in a statement that members would remain on strike — scuttling those plans and prompting Air Canada to cancel some 240 flights. WATCH | Hundreds of flight attendants picket at Vancouver airport: Hundreds of Air Canada flight attendants picket in Vancouver 18 hours ago Hundreds of Air Canada flight attendants demonstrated outside Vancouver International Airport on Saturday. The strike prompted a warning for passengers to avoid the airport unless they have confirmed a booking on a different airline. Shaurya Kshatri reports. At Vancouver International Airport, passengers stood in long lines to get the latest updates on their delayed and cancelled flights, as workers outside demonstrated with signs reading, "Unpaid work won't fly." Chi Ehis told The Canadian Press she is having to pay an extra $2,000 to meet her family in Florida for a vacation after her flight was cancelled Sunday morning. Instead of flying straight from Vancouver, she is now taking a bus to Seattle before catching another, pricier flight. "I can't scream. I have to just figure out what to do," Ehis said, adding her plane ticket cost $1,500. WATCH | Tips for Air Canada passengers from travel influencer Moxey Munch: CBC's Mark Carcasole speaks with Moxey Munch on tips for Air Canada customers 3 hours ago CBC's Mark Carcasole speaks with Moxey Munch on tips for Air Canada customers In Toronto, Khalid Muhammadi told CBC News he flew in from Dubai en route to Edmonton but is now stuck at Pearson International Airport. "WestJet is asking eight grand; what am I supposed to do?" he said. Muhammadi voiced frustrations with the federal government for not resolving the labour dispute. "You knew a strike was coming ... do your job." Air Canada has said passengers whose flights are cancelled will be offered a full refund or the opportunity to change their travel plans without a fee. However, it said that under Canada's airline passenger protection regulations, customers are not eligible for compensation for expenses incurred during travel delays deemed outside the airline's control. "Customers in Canada are not eligible for compensation for delayed or cancelled flights, meals, hotels or other incidental expenses for situations outside the carrier's control, such as a labour disruption," the airline said.
Edmonton Journal
7 hours ago
- Edmonton Journal
Air Canada flight attendants defy back-to-work order, continue strike
Article content Oci Mara and her husband were supposed to fly home to Montreal at around 1 a.m. Monday, but their flights were cancelled due to the strike. Unable to get through by phone, they went to the airport to speak with Air Canada agents in person. Article content 'It's a terrible situation. It's so frustrating,' Mara said, adding that her husband needs to be back in Montreal for work on Monday. Article content Mara said they were told that if they booked seats with another airline, Air Canada would only refund the cost of their original tickets. Article content 'We have no idea what we're going to do,' she said. Article content While she sympathizes with flight attendants fighting for fair pay, Mara said the strike has left passengers struggling to make alternate travel arrangements. Article content 'I understand people have to fight for their rights to get paid,' she said. 'Unfortunately, there's a lot of problems for us (as a result).' Article content Article content Air Canada said it will provide travellers with cancelled flights options such as full refunds or credit for future travel. 'The carrier will also offer to rebook customers on other carriers, although capacity is currently limited due to the peak summer travel season,' the airline said in a statement. Article content Article content Flight attendants spent Saturday picketing at the Calgary International Airport, where travellers continued their efforts to salvage travel plans disrupted by the work stoppage. Article content Air Canada, which locked out its flight attendants shortly after their strike began, had planned for flights to resume Sunday evening with a gradual ramp-up over the coming days, the Montreal-based airline said in a statement. Whenever service restarts, it will take several days before operations return to normal. Article content Article content The airline previously said the walkout would disrupt some 130,000 passengers a day during the summer holiday season. Article content The Canada Industrial Relations Board directed Air Canada to resume airline operations and for all Air Canada and Air Canada Rouge flight attendants to return to work by 2 p.m. ET, according to the airline's statement early Sunday. Article content The move came after Jobs Minister Patty Hajdu directed the independent CIRB to order a resumption of operations and to impose binding arbitration to resolve a standoff over contract negotiations. Article content The Liberal government's back-to-work order was criticized by the government's political opponents on Saturday. Article content Federal Conservative Labour critic Kyle Seeback called the move an attack on flight attendants. Article content 'No worker — federally regulated or otherwise — should be forced, especially by the government, to work without being paid. Yet, that is exactly what flight attendants are being ordered to do,' he said in a written statement, while urging the federal Liberals to pass a Conservative-sponsored bill that would ensure flight attendants are paid for all hours worked. Article content Meanwhile, Alberta NDP Leader Naheed Nenshi said the Air Canada labour dispute should be resolved at the negotiating table.
CBC
7 hours ago
- CBC
Want Air Canada to reroute your flight? Prepare for 'turbulence,' says this passenger
Air Canada says it plans to restart flights Monday evening after striking flight attendants defied the federal government's back-to-work order Sunday morning. For Lila Rousseaux, a longtime Air Canada customer, the weekend work stoppage has resulted in inflexibility from the airline as she and her family try to reroute their way home.
